Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 249 | 52 | 191 |
| Samples | 238 | 48 | 185 |
| Peptides | 185 | 35 | 148 |
Function
CLPX · Caseinolytic mitochondrial matrix peptidase chaperone subunit X
The protein encoded by this gene is part of a protease found in mitochondria. This protease is ATP-dependent and targets specific proteins for degradation. The protease consists of two heptameric rings of the CLPP catalytic subunit sandwiched between two hexameric rings of the chaperone subunit encoded by this gene. Targeted proteins are unwound by this protein and then passed on to the CLPP subunit for degradation. Two transcript variants, one protein-coding and the other non-protein coding, have been found for this gene. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000300107 | O76031 | 249 | 185 |
Gene Properties
Recurrent Mutations
All 185 amino-acid changes on canonical ENST00000300107 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CLPX · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CLPX – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 20/612 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Bladder Carcinoma | 1/58 2% | 14/956 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Melanoma | 4/210 2% | 24/1899 1% |
| Colorectal Carcinoma | 6/143 4% | 35/3239 1% |
| Plasma Cell Myeloma | 2/44 5% | 2/305 1% |
| Cervical Carcinoma | 4/35 11% | 1/422 0% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Burkitts Lymphoma | 1/32 3% | 1/196 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Gastric Carcinoma | 0/74 0% | 13/1809 1% |
| Neuroendocrine Tumour | 3/154 2% | 2/577 0% |
| Other Solid Cancers | 3/94 3% | 7/1515 0% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Hepatocellular Carcinoma | 2/46 4% | 8/2210 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 6/1390 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Neuroblastoma | 4/87 5% | 1/1331 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Breast Carcinoma | 1/144 1% | 8/3264 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Glioma | 0/52 0% | 4/2127 0% |
Mutation Distribution
Where CLPX is mutated · all tissues, split by cell line vs tissue
How many mutations in CLPX were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 249 mutations in CLPX
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|